MUFG Investor Services to Buy Maitland’s Hedge Fund Administration Unit (Verdict.co.uk)
MUFG Investor Services, a global asset servicing business owned by Mitsubishi UFJ Financial Group (MUFG), has agreed to purchase select divisions of Maitland’s fund administration arm. The transaction value was not revealed. The assets to be acquired include hedge funds and private equity funds, which will add around $20bn in assets under administration to MUFG Investor Services’ existing portfolio of more than $580bn.
Elliott and Blackstone Enter Hostile Territory in Japan (The Washington Post)
A small $1.5 billion company is attracting the biggest movers in finance in what’s shaping up as the first high-profile foreign hostile takeover in Japan. If successful, it could wake up the sleepy $228 billion market of publicly listed real-estate companies. The attention is on Unizo Holdings Co., until recently an obscure developer and hotel operator. The company has a big chunk of its office rental business, which accounts for about 90% of operating income, in Tokyo, where the vacancy rate is as low as 2% and a decent 3.5% yield can be earned.
Acadia Pharmaceuticals Inc (ACAD) CEO Stephen Davis Sold $6 million of Shares (Guru Focus)
CEO of Acadia Pharmaceuticals Inc., Stephen Davis, sold 150,000 shares of ACAD on 10/10/2019 at an average price of $40.15 a share. The total sale was $6 million. ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson’s, Alzheimer’s and schizophrenia.
Notable Insider Buys In The Past Week: Assured Guaranty, Red Rock Resorts, TerraForm Power (Benzinga)
The following are some notable insider purchases reported in the past week, ahead of the new earnings reporting season. TerraForm Power: TerraForm Power Inc (TERP) 0.41% 10% owner Brookfield Asset Management stepped up to the buy window this past week. The firm picked up over 2.98 million shares of this clean power generation asset holder at $16.77 each last week. That transaction totaled about $50 million, and it brought the firm’s stake to nearly 32.86 million shares.
Arrowhead Pharmaceuticals Inc (ARWR) CEO Christopher Richard Anzalone Sold $1.8 million of Shares (Guru Focus)
CEO of Arrowhead Pharmaceuticals Inc., Christopher Richard Anzalone, sold 56,325 shares of ARWR on 10/10/2019 at an average price of $31.83 a share. The total sale was $1.8 million. Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
